Skip to content

MAZE MAZE Return on assets

Return on assets at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
17.6%
Septerna, Inc. logo
Septerna, Inc.SEPN
-7.2%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
-39.9%-56.4pp
Zymeworks logo
ZymeworksZYME
-22.7%-0.5pp
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
-47.2%+2.5pp
MapLight Therapeutics, Inc.
 logo
MapLight Therapeutics, Inc. MPLT
-52.3%

Other financials

Income statement

See full
Revenue$20.0M
Operating income-$26.6M+25.0%
Net income-$24.2M+26.2%
EPS (diluted)-$0.45+60.9%

Balance sheet

See full
Cash & equivalents$198.8M-32.5%
Total debt$61.2M+137%
Total equity$341.7M+17.0%
Total assets$419.7M+26.1%

Cash flow

See full
Operating cash flow-$39.1M-32.5%
CapEx$93.0K-68.9%
Free cash flow-$39.2M-31.5%

Valuation

See full
Market cap$1.48B
Enterprise value$1.34B
P/S7.9×

Profitability

See full
Operating margin-71.5%
Net margin-65.4%
FCF margin-65.1%

Returns & leverage

See full
Return on equity-38.7%
Debt / equity0.2×+0.1×
Current ratio17.9×+1.8×

Where this comes from

Calculated from MAZE’s reported figures.

Based on trailing twelve months.

The official record: MAZE’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about MAZE's return on assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MAZE's return on assets?
MAZE (MAZE) reported return on assets of -32.6% in Q1 2026.
What does return on assets mean?
Trailing-twelve-month net income divided by average total assets. Measures how efficiently the asset base generates profit, independent of how those assets are financed. Computed as net income over average total assets — note this is OpenCapital's standard definition and may differ from data vendors that use alternative numerators.